CSF2 and melanoma: Talimogene laherparepvec is an oncolytic virotherapy consisting of genetically modified HSV-1 containing the human granulocyte-macrophage colony-stimulating factor (GM-CSF) gene and has been FDA approved for the treatment of melanoma [58].